Fig. 3
Changes in neurodegeneration and astrogliosis biomarkers in plasma p-tau217 ‘positive’ participants following AADvac1 treatment. The treatment differences in the change from baseline at week 104 in neuroimaging and plasma biomarkers in the plasma p-tau217 ‘positive’ participants were analyzed by MMRM: (A), 6% (95% CI, −20.9 to 33.3, P = 0.66) in the whole brain volume; (B), 29% (95% CI, −8.4 to 66.7; P = 0.13) in the entire cortical tissue; (C), 27% (95% CI, −0.61 to 55.4; P = 0.06) in the temporal cortex; (D), 32% (95% CI, −17.6 to 81.0; P = 0.21) in the frontal cortex; (E), 56% (95% CI, 19.4 to 93.1, P = 0.003) in plasma NfL (log10-transformed concentrations); (F), 73% (95% CI, 14.2 to 131.5, P = 0.02) in plasma GFAP (log10-transformed concentrations). All the MMRM models were adjusted for variables as described in the Methods section. FAS, the positive participants were selected from the full analysis set. The error bars indicate the standard error. The dotted line indicates the baseline